Bimatoprost CAS 155206-00-1 Raw Materials Powder

CAS: 155206-00-1

MF: C25H37NO4

MW: 415.57

Specification​: 99% min Bimatoprost

Sample: Bimatoprost Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Bimatoprost Powder Usage and Synthesis.

Bimatoprost Powder is a drug, also known as a prostaglandin inhibitor, used to treat prostate hyperplasia and prostate cancer. It reduces the volume of prostate tissue and relieves symptoms such as frequent, urgent, and painful urination. Bimatoprost CAS 155206-00-1 is a non-selective alpha1-adrenergic receptor antagonist that blocks the release of epinephrine and norepinephrine from nerve endings and reduces blood flow to prostate tissue. In addition, Bimatoprost Raw Materials can reduce the tension of bladder muscles, increase bladder capacity and Usually, Bimatoprost needs to be used for a long time to achieve optimal results.

Application/Function of Bimatoprost Powder.

Bimatoprost is a prostaglandin drug that was first used to treat eye diseases such as glaucoma under the name Lumigan. However, during the treatment, the patient unexpectedly noticed a significant increase in the diameter, length and density of his eyelashes. Bimatoprost has since been used in clinical trials for cosmetic eyelash enhancement and its tremendous effect on thickening and thickening of eyelashes.

Bimatoprost is a synthetic prostamide F2α derivative that selectively mimics the effect of prostamide produced in vivo, increasing the rate of atrial aqueous production and decreasing the resistance to atrial outflow, reducing intraocular pressure (IOP) by increasing atrial aqueous outflow from trabecular meshwork channels and uveoscleral channels, and is considered to be the strongest topical anti-glaucoma drug for lowering IOP. It is indicated for the treatment of patients with open-angle glaucoma (POAG) or ocular hypertension (OHT) who have failed to respond to other IOP-lowering drugs.

Bimatoprost-Timolol Maleate Combination Eye Drops In July 2006, Bimatoprost-Timolol Maleate Combination Eye Drops, developed by Eye Health USA, Inc. was approved by the European Union drug authorities for the reduction of intraocular pressure or ocular hypertension in patients with open-angle glaucoma who have not responded adequately to treatment with beta-blockers or prostaglandin analogs alone. The combination drops, containing 0.03% bimatoprost and 0.5% timolol maleate, provide clinically very effective intraocular pressure control when administered once a day and are superior to bimatoprost or timolol maleate alone. Clinical trials have demonstrated excellent tolerability of the drug, including a 40% lower incidence of ocular congestion than with bimatoprost alone.

Pharmacological effects of Bimatoprost Powder

Olaparib has been used to treat BRCA mutated tumors, such as ovarian, breast, and prostate cancers. prostate cancer. In addition, Olaparib inhibits ATM-deficient tumor cells selectively, suggesting that Olaparib may be a potential agent for the treatment of ATM-mutated lymphoma.